{
    "id": 475,
    "fullName": "EZH2 Y641N",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EZH2 Y641N lies within the SET domain of the Ezh2 protein (PMID: 24362326). Y641N confers a gain of function to the Ezh2 protein, as demonstrated by increased trimethylation of H3K27 in an in-vitro assay (PMID: 21078963), in B-cell lymphoma cells in culture (PMID: 21190999) and in breast cancer cell lines (PMID: 25253781).",
            "references": [
                {
                    "id": 149,
                    "pubMedId": 24362326,
                    "title": "EZH2: biology, disease, and structure-based drug discovery.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24362326"
                },
                {
                    "id": 2703,
                    "pubMedId": 21078963,
                    "title": "Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21078963"
                },
                {
                    "id": 505,
                    "pubMedId": 21190999,
                    "title": "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190999"
                },
                {
                    "id": 12214,
                    "pubMedId": 25253781,
                    "title": "A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25253781"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2146,
        "geneSymbol": "EZH2",
        "terms": [
            "EZH2",
            "ENX-1",
            "ENX1",
            "EZH2b",
            "KMT6",
            "KMT6A",
            "WVS",
            "WVS2"
        ]
    },
    "variant": "Y641N",
    "createDate": "05/02/2014",
    "updateDate": "09/16/2018",
    "referenceTranscriptCoordinates": {
        "id": 171528,
        "transcript": "NM_001203247",
        "gDna": "chr7:g.148811636A>T",
        "cDna": "c.1921T>A",
        "protein": "p.Y641N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6625,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641N treated with the combination of ACY-957 and Adriamycin (doxorubicin) resulted in a greater sensitivity to cell death compared to treatment with either agent alone (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 4187,
                "therapyName": "ACY-957 + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6563,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 alone did not alter cell-cycle progression in survival in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6558,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 4148,
                "therapyName": "ACY-957 + GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6551,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 4144,
                "therapyName": "ACY-957",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5614,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641N in culture (PMID: 26936398).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5127,
                    "pubMedId": 26936398,
                    "title": "Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6560,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 4147,
                "therapyName": "ACY-957 + DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6554,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1426,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UNC1999 treatment reduced H3K27me3 levels, decreased proliferation, and increased cell death in diffuse large B-cell lymphoma cells harboring an EZH2 Y641N mutation in cell culture (PMID: 23614352).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 1757,
                "therapyName": "UNC1999",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1266,
                    "pubMedId": 23614352,
                    "title": "An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23614352"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6565,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZNeP treatment resulted in an increase in the number of dead or sub-G1 cells and increased DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 2702,
                "therapyName": "DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11145,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture and delayed tumor growth and tumor regression in a cell line xenograft model (PMID: 28135235).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 5886,
                "therapyName": "EED226",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11151,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EED226 and EI1 synergistically inhibited cell proliferation in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 28135235).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 5887,
                "therapyName": "EED226 + EI1",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9115,
                    "pubMedId": 28135235,
                    "title": "An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28135235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 672,
            "profileName": "EZH2 Y641N",
            "profileTreatmentApproaches": [
                {
                    "id": 4591,
                    "name": "EZH2 inhibitor",
                    "profileName": "EZH2 Y641N"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171528,
            "transcript": "NM_001203247",
            "gDna": "chr7:g.148811636A>T",
            "cDna": "c.1921T>A",
            "protein": "p.Y641N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171529,
            "transcript": "XM_011515889",
            "gDna": "chr7:g.148810375A>T",
            "cDna": "c.1921T>A",
            "protein": "p.Y641N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}